GSK plc reports

6-K File 001-15170

STATEMENT: ZANTAC (RANITIDINE) LITIGATION

Filing date

24 May 2024

Reporting date

24 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB

Filing date

21 May 2024

Reporting date

21 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

20 May 2024

Reporting date

20 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

CURRENT REPORT

Filing date

17 May 2024

Reporting date

17 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

GSK COMPLETES SALE OF SHARES IN HALEON PLC

Filing date

17 May 2024

Reporting date

17 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

14 May 2024

Reporting date

14 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

BLOCK LISTING INTERIM REVIEW

Filing date

13 May 2024

Reporting date

13 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

RESULT OF AGM

Filing date

08 May 2024

Reporting date

08 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

BOARD COMMITTEE CHANGE

Filing date

08 May 2024

Reporting date

08 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

03 May 2024

Reporting date

03 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

1ST QUARTER RESULTS

Filing date

01 May 2024

Reporting date

01 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date

01 May 2024

Reporting date

01 May 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI

Filing date

24 Apr 2024

Reporting date

24 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

19 Apr 2024

Reporting date

19 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

17 Apr 2024

Reporting date

17 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX

Filing date

17 Apr 2024

Reporting date

17 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS

Filing date

17 Apr 2024

Reporting date

17 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

AMENDMENT - DIRECTOR/PDMR SHAREHOLDING

Filing date

16 Apr 2024

Reporting date

16 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE

Filing date

16 Apr 2024

Reporting date

16 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

15 Apr 2024

Reporting date

15 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K/A File 001-15170

REPLACEMENT - TOTAL VOTING RIGHTS

Filing date

04 Apr 2024

Reporting date

04 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date

02 Apr 2024

Reporting date

02 Apr 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

SC 13D/A

AMENDMENT TO FORM SC 13D

Filing date

28 Mar 2024

Reporting date

Not listed

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

26 Mar 2024

Reporting date

26 Mar 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

F-3ASR File 333-278205

F-3ASR

Filing date

25 Mar 2024

Reporting date

Not listed

SEC evidence

Open document Open filing

Next action

Verify source filing